Abstract
Colorectal cancer is the third most prevalent cancer in the world. If detected at an early stage, treatment often might lead to cure. As prevention is better than cure, epidemiological studies reveal that having a healthy diet often protects from promoting/developing cancer. An important consideration in evaluating new drugs and devices is determining whether a product can effectively treat a targeted disease. There are quite a number of biomarkers making their way into clinical trials and few are awaiting the preclinical efficacy and safety results to enter into clinical trials. Researchers are facing challenges in modifying trial design and defining the right control population, validating biomarker assays from the biological and analytical perspective and using biomarker data as a guideline for decision making. In spite of following all guidelines, the results are disappointing from many of the large clinical trials. To avoid these disappointments, selection of biomarkers and its target drug needs to be evaluated in appropriate animal models for its toxicities and efficacies. The focus of this review is on the few of the potential molecular targets and their biomarkers in colorectal cancers. Strengths and limitations of biomarkers/surrogate endpoints are also discussed. Various pathways involved in tumor cells and the specific agents to target the altered molecular biomarker in biomolecular pathway are elucidated. Importance of emerging new platforms siRNAs and miRNAs technology for colorectal cancer therapeutics is reviewed.
Similar content being viewed by others
Article PDF
References
O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002; 8: 314–46.
Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA . Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J Cell Biochem Suppl 1992; 16: 55–62.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277–84.
Herschman H . Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125–40.
Spencer AG, Thuresson E, Otto JC, Song I, Smith T, DeWitt DL, et al. The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis. J Biol Chem 1999; 274: 32936–42.
Smith WL . Prostanoid biosynthesis and mechanism of action. Am J Physiol 1992; 263: 181–91.
Lee SH, Soyoola E, Chanmugam P, Hart S, Zhong H, Liou S et al. Selective expression of mitogen inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934–8.
O'Neill GP, Ford-Hutchinson AW . Expression of RNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–60.
Marnett LJ . Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575–89.
Rigas B, Goldman IS, Levine L . Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518–23.
Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609–14.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN . Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8.
Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785–9.
Aurelie T, Christophe F, Nicole P, Jean-Pierre H . Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 2006; 6: 187–208.
DuBois RN, Radhika A, Reddy BS, Entingh AJ . Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1259–62.
Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816–20.
Tsujii M, Kawano S, DuBois RN . Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–40.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN . Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–16.
Masferrer, JL, Kathleen ML, Alane TK, Ben SZ, Steven LS, Mark BW, et al. Antiangiogenic and antitumor activities of cyclooxygenase 2 inhibitors. Cancer res 2000; 60: 1306–11.
Dimberg J, Samuelsson A, Hugander A, Söderkvist P . Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999; 45: 730–2.
Richard F, Matthias S, Klaus-Peter T, Christoph HG, Peter F . Cyclooxygenase-2 Expression in Human Colorectal Cancer Is Unrelated to Overall Patient Survival. Clin Cancer Res 2005; 11: 4754–60.
Chan AT, Ongino S, Charles SF . Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007, 356; 2131–42.
DuBois RN, Smalley WE . Cyclooxygenase, NSAIDs and colorectal cancer. J Gastroenterol 1996; 31: 898–906.
Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254–9.
Rayyan Y, Williams J, Rigas B . The role of NSAIDs in the prevention of colon cancer. Cancer Invest 2002; 20: 1002–11.
Gupta RA, Dubois RN . Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11–21.
Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 1463 65–75.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91.
Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80.
Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C . Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007; 146: 376–89.
Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV . Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention. Mol cancer Ther 2004; 3: 215–21.
DuBois RN . New paradigms for cancer prevention. Carcino-genesis 2001; 22: 691–2.
Rigas B, Kashfi K . Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004; 10: 324–30.
Yeh RK, Chen J, Williams JL, Baluch M, Hundley TK, Rosenbaum RE, et al. NO-donating nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 2004; 67: 2197–205.
Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 2005; 312: 978–88.
Rao CV, Reddy BS, Steele VE, Wang C-X, Liu X, Ouyang N, et al. Nitric oxide–releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006; 5: 1530–8.
Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Soldato Pd, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 2002; 303: 1273–82.
Gao J, Liu X, Rigas B . Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA 2005; 102: 17207–12.
Hundley TR, Rigas B . Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J Pharmacol Exp Ther 2006; 316: 25–34.
Fries S, Grosser T, Price T, Lawson J, Kapoor S, DeMarco S, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130: 55–64.
Bogdan C . Nitric oxide and the immune response. Nat Immunol 2001; 2: 907–16.
Lala PK, Chakraborty C . Role of nitric oxide in carcinogenesis and tumor progression. Lancet Oncol 2001; 2: 149–56.
Wink DA, Vodovotz Y, Cook JA, Krishna MC, Kim S, Coffin D, et al. The role of nitric oxide chemistry in cancer treatment. Biochemistry 1998; 63: 802–9.
Chhatwal VJ, Ngoi SS, Chan ST, Chia YW, Moochhala SM . Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding preitumoral normal mucosa. Carcinogenesis 1994; 15: 2081–5.
Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Oqunfusika MO, Osen SM, et al. Frequent nitric oxide synthase 2 expression in human colon adenomas: implication for tumor angio-genesis and colon cancer progression. Cancer Res 1998; 58: 334–41.
Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Harrington AM, et al. Relationship between p53 Mutations and Inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999; 91: 86–8.
Kojima M, Morisaki T, Tsukahara Y, Uchiyama A, Matsunari Y, Mibu R, et al. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J Surg Oncol 1999; 70: 222–9.
Fransen K, Dimberg J, Osterström A, Olsson A, Söderkvist P, Sirsjö A . Nitric oxide synthase 2 mRNA expression in relation to p53 and adenomatous polypsis coli mutations in primary colorectal adenomas. Surgery 2002; 131: 384–92.
Moochhala S, Chhatwal VJS, Chan STF, Ngoi SS, Chia YW, Rauff A . Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 1996; 117: 1171–4.
Hofseth LJ, Hussain SP, Wogan GN, Harris CC . Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003; 34: 955–68.
Crowell JA, Steele VE, Sigman CC, Fay JR . Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2003; 2: 815–23.
Ahn B, Ohshima H . Suppression of intestinal polyposis in ApcMin/+ mice by inhibiting nitric oxide production. Cancer Res 2001; 61: 8357–60.
Nam KT, Oh SY, Ahn B, Kim YB, Jang DD, Yang KH, et al. Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut 2004; 53: 1250–5.
Rao CV, Kawamori T, Hamid R, Reddy BS . Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999; 20: 641–4.
Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS . Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002; 62: 165–70.
Xu W, Liu L, Charles IG . Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J 2002; 16: 213–5.
Thomsen, LL, Scott JMJ, Topley P, Knowles RG, Keerie AJ, Frend AJ . Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res 1997; 57: 3300–4.
Scott D, Hull MA, Cartwright EJ, Lam W, Tisbury A, Poulsom R, et al. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the ApcMin/+ mouse. Gastroenterology 2001; 121: 889–99.
Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 2004; 64: 6849–53.
Kim SF, Huri DA, Snyder SH . Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005; 310: 1966–70.
Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413–22.
Järvinen R, Knekt P, Hakulinen T, Rissanen H, Heliövaara M . Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer 2001; 85: 357–61.
Lipkin M, Yang K, Edelmann W, Xue L, Fan K, Risio M . Pre-clinical mouse models for cancer chemoprevention studies. Ann N Y Acad Sci 1999; 889: 14–9.
Goldstein JL, Brown MS . Regulation of the mevalonate pathway. Nature 1990; 343: 425–30.
Wachtershauser A, Akoglu B, Stein J . HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcino-genesis 2001; 22: 1061–7.
Hentosh P, Yuh SH, Elson CE, Peffley DM . Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 2001; 32: 154–66.
Mason JC . Statins and their role in vascular protection. Clin Sci (London) 2003; 105: 251–66.
Crisby M . Modulation of the inflammatory process by statins. Drugs Today (Barcelona) 2003; 39: 137–43.
Bjerre LM, Lelorier J . Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001; 110: 716–23.
Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184–92.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9.
Downs JR, Clearfield DO, Weis S, Whitney E, Shapiro D, Beere P, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615–22.
Blais L, Desgagne A, LeLorier J . 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363–8.
Probstfield JL, Davis BR . Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002; 288: 2998–3007.
Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H . The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388–94.
Kaye JA, Jick H . Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635–7.
Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643–47.
Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE . Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006; 98: 69–72.
Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, Yazawa K, et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994; 15: 2045–48.
Narisawa T, Fukaura Y, Tanida N, Hasebe M, Ito M, Aizawa R . Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996; 180: 131–8.
Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, Aizawa R . Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996; 87: 798–804.
Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effect of sulindac. Gastroenterology 1999; 117: 838–47.
Rao CV, Newmark HL, Reddy BS . Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detect Prev 2002; 26: 419–25.
Kim KP, Whitehead C, Piazza G, Wargovich MJ . Combinatorial chemoprevention: efficacy of lovastatin and exisulind on the formation and progression of aberrant crypt foci. Antican-cer Res 2004; 24: 1805–11.
Reddy BS, Wang CX, Kong AN, Khor TO, Zheng Xi, Steele VE, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F344 rats. Cancer Res 2006; 66: 4542–6.
Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, et al. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression for G1-S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997; 272: 13–6.
Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, et al. Inhibition of the 3-hydroxy-3 methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998; 273: 10618–23.
Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22: 1139–48.
Wachtershauser A, Akoglu B, Stein J . HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcino-genesis 2001; 22: 1061–7.
Swamy MV, Cooma I, Reddy BS, Rao CV . Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 2002; 20: 753–9.
Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ . Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866–70.
Sporn MB, Suh N . Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002; 2: 537–43.
Shulman AI, Mangelsdorf DJ . Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005; 353: 604–15.
Darwiche N, Scita G, Jones C, Rutberg S, Greenwald E, Tennenbaum T, et al. Loss of retinoic acid receptors in mouse skin and skin tumors is associated with activation of the rasHa oncogene and high risk for premalignant progression. Cancer Res 1996; 56: 4942–9.
Jiang SY . Expression of nuclear retinoid receptors in normal, premalignant and malignant gastric tissues determined by in situ hybridization. Br J Cancer 1999; 80: 206–14.
Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001; 193: 827–38.
Xiao JH, Ghosn C, Hinchman C, Forbes C, Wang J, Snider N, et al. Adenomatous polyposis coli (APC)-independent regulation of β-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 2003; 278: 29954–62.
Mangelsdorf DJ, Evans RM . The RXR heterodimers and orphan receptors. Cell 1995; 83: 841–50.
Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM . Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990; 345: 224–29.
Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong US, Evans RM . A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 1991; 66: 555–61.
Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68: 397–406.
Mukherjee, R, Davies PJA, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407–10.
Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW . Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res 1998; 58: 479–84.
Wu K, Kim N-T, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD 1069. Cancer Epidemiol Biomarkers Prev 2002; 11: 467–74.
Boehm MF, Zhang L, Zhi Li, McClurg MR, Berger E, Wagoner Mu, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38: 3146–55.
Vuligonda V, Thacher SM, Chandraratna RA . Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. J Med Chem 2001; 44: 2298–303.
Deroo JB, Korach KS . Estrogen receptors and human disease. J Clin Invest 2006; 116: 561–70.
Chambliss KL, Yuhanna IS, Anderson RGW, Mendelsohn ME, Shaul PW . ERβ has nongenomic action in caveolae. Mol Endocrinol 2002; 16: 938–46.
Govind AP, Thampan RV . Membrane associated estrogen receptors and related proteins: Localization at the plasma membrane and the endoplasmic reticulum. Mol Cell Biochem 2003; 253: 233–40.
Zivadinovic D, Watson SC . Membrane estrogen receptor-α levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res 2005; 7: R130–44.
Levin ER . “Integration of the extranuclear and nuclear actions of estrogen.” Mol Endocrinol 2005; 19: 1951–9.
Calle EE, Miracle-McMahill HL, Thun MJ, Health CW Jr . Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 517–23.
Newcomb PA, Storer BE . Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995; 87: 1067–71.
Singh S, Langman MJ . Oestrogen and colonic epithelial cell growth. Gut 1995; 37: 737–9.
Grodstein F, Newcomb PA, Stampfer MJ . Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med 1999; 106: 574–84.
Olofinlade O, Grewal P, Gualtieri N . Colorectal carcinoma in young female patients. Gastroenterology 2000; 118, Suppl 2: A756.
Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN . Evidence of healthy estrogen user survivor effect. Epidemiology 1995; 6: 227–31.
kampman E, potter JD, slattery ML, can BJ, Edwards S . Hormone replacement therapy, reproductive history, and colon cancer: a multicenter case-control study in the United States. Cancer Causes Control 1997; 8: 146–58.
Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni JF Jr . A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes Control 1997: 8: 130–8.
Fernandez E, La Vecchia C, Braga C, talamini R, Negri E, Parazzini F, et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 329–33.
Womens Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The women's Health Initiative randomized Controlled Trial. JAMA 2004; 291: 1701.
Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–50.
Waliszewski P, Blaszczyk M, Wolinska-Witort E, Drews M, Snochowski M, Hurst RE . Molecular study of sex steroid receptor gene expression in human colon and in colorectal carcinomas. J Surg Oncol 1997; 64: 3–11.
Raigoso P, Sanz L, Vizoso F, Ilana B, Quintela I, Roibas A, et al. Estrogen and progesterone receptors in colorectal cancer and surrounding mucosa. Int J Biol Markers 2001; 16: 262–7.
Speer G, Cseh K, Winkler G, Takács I, Barna I, Nagy Z, et al. Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. Eur J Cancer 2001; 37: 1463–8.
Witte D, Chirala M, Younes A, Li Y, Younes M . Estrogen receptor β is expressed in human colorectal adenocarcinoma. Hum Pathol 2001; 32: 940–4.
Berta L, Fronticelli Baldelli C, Fazzari A, Radice E, Bargoni A, Frairia R, et al. Sex steroid receptors, secondary bile acids and colorectal cancer. A possible mechanism of interaction. Panminerva Med 2003; 45: 261–6.
Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39: 1251–8.
Javid SH, Moran AE, Carothers AM, Redston M, Bertagnolli MM . Modulation of tumor formation and intestinal cell migration by estrogens in the ApcMin/+ mouse model of colorectal cancer. Carcinogenesis 2005; 26: 587–95.
Narayan S, Rajakumar G, Prouix H, Singh P . Estradiol is trophic for colon cancer in mice: Effect on omithine decarboxylase and c-myc messenger RNA. Gastroenterology 1992; 103: 1823–32.
Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, et al. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 2000; 55: 163–93.
Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000; 74: 279–85.
Di Leo A, Messa C, Russo F, Misciagna G, Guerra V, Taveri R, et al. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results. Dig Dis Sci 1994; 39: 2038–42.
Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW . Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000; 60: 245–8.
Campbell-Thompson M, Lynch IJ, Bhardwaj B . Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001; 61: 632–40.
Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC . Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol 2002; 174: 369–77.
Cho NC, Javid SH, Carothers AM, Redston M, Bertagnoll MM . Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007; 67: 2366–72.
Jassam N, Bell SM, Speirs V, Quirke P . Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes'staging. Oncol Rep 2005; 14: 17–21.
Xie L, Yu J, Luo H . Expression of estrogen receptor beta in human colorectal cancer. World J Gastroenterol 2004; 10: 214–17.
Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, et al. Role of estrogen receptor β in colonic epithelium. Proc Natl Acad Sci USA 2006; 103: 2959–64.
Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N . Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 2005; 239: 27–36.
Kuruppu D, Christophi C, Bertram JF, OBrien PE . Tamoxifen inhibits colorectal cancer metastases in the liver: A study in a murine model. J Gastroenterol Hepatol 1998; 13: 521–7.
Rutqvist L, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N . Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645.
Grodstein R, Newcomb PA, Stampfer MJ . Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med 1999; 106: 574.
Cook L, Weiss N, Pharris-Ciurej N, Schwartz S, White E . Colorectal cancer following tamoxifen therapy for breast cancer (United States). Cancer Causes Control 2001; 12: 405.
Fabian CJ, Kimler BF . Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005; 23: 1644–55.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effect of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727–41.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637–45.
Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al. Skeletal effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005; 20: 1514–24.
Picariello L, Fiorelli G, Martineti V, Tognarini I, Pampaloni B, Tonelli F, et al. growth response of colon cancer cell lines to selectve estrogen receptor modulators. Anticancer Res 2003; 23: 2419–24.
Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258–65.
Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, et al. Associations between ERα, ERβ, and AR Genotypes and Colon and Rectal Cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2936–42.
Cadigan KM, Nusse R . Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286–305.
Huelsken J, Birchmeier W . New aspects of Wnt signaling pathways in higher vertebrates. Curr Opin Genet Dev 2001; 11: 547–53.
Lee HK, Choi YS, Park YA, Jeong S . Modulation of oncogenic transcription and alternative splicing by β-catenin and an RNA aptamer in colon cancer cells. Cancer Res 2006; 66: 10560–6.
Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC . Interaction of nuclear receptors with the Wnt/β-catenin/Tcf signaling axis: Wnt you like to know? Endocrine Rev 2005; 26: 898–15.
Kouzmenko AP, Takeyama K-I, Ito S, Furutani T, Sawatsubashi S, Maki A . Wnt/β-catenin and estrogen signaling converge in vivo. J Biol Chem 2004; 279: 40255–8.
Powell SM, Zilk N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235–7.
Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P . Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 1996; 272: 1023–6.
Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996; 382: 638–42.
Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S . Axin, a negative regulator of the Wnt signalling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. EMBO J 1998; 17: 1371–84.
Sakanaka C, Weiss JB, Williams LT . Bridging of β-catenin and glycogen synthase kinase-3β by axin and inhibition of β-catenin-mediated transcription. Proc Natl Acad Sci USA 1998; 95: 3020–3.
Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK-3β. Science 1998; 280: 596–9.
Sparks AB, Morin PJ, Vogelstein B, Kinzler KW . Mutational analysis of the APC/β-Catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 1130–4.
Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382: 638–42.
Hugh TJ, Dillon SA, O'Dowd G, Getty B, Pignatelli M, Poston GJ, et al. Beta-catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer 1999; 82: 504–11.
Wong NA, Pignatelli M . β-catenin - A linchpin in colorectal carcinogenesis? Am J Pathol 2002; 160: 389–401.
Yang J, Zhang W, Evans PM, Chen X, He X, Liu C . Adenomatous polyposis coli (APC) differentially regulates β-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006; 281: 17751–7.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787–90.
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784–7.
Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al. Wnt/B-catenin signaling pathway as novel cancer drug targets. Curr Cancer Drug Targets 2004; 4: 653–71.
Dihlmann S, von Knebel Doeberitz M . Wnt/β-catenin-path-way as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005; 113: 515–24.
de Vogel S, van Engeland M, Luchtenborg M, de Bruine AP, Roemen GM, Lentjes MH, et al. Dietary folate and APC mutations in sporadic colorectal cancer. J Nutr 2006; 136: 3015–21.
Cole F, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas. JAMA 2007; 297: 2351–9.
Nath N, Kashfi K, Chen J, Rigas B . Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin-TCF association. Proc Natl Acad Sci USA 2003; 100: 12584–9.
Dean NM, Bennett CF . Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003; 22: 9087–96.
Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 2004; 5: 91–102.
Prolexys Pharmaceuticals[homepage on the Internet]. Small Molecule Inhibitors of the Beta-catenin Pathway. [updated 2007 Dec 1; cited 2007 Dec 20] Available from: http://www.prolexys.com/public/Prolexys_Beta-Catenin.pdf.
Borgeat P, Hamberg M, Samuelsson B . Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem 1976; 251: 7816–20.
Ye YN, Liu ESL, Shin VY, Cho CH . Involvement of 5-lipoxygenase, matrix metalloproteinase-2 and vascular endothelial growth factor in the colonic tumorigenesis promoted by passive cigarette smoking. Am Assoc Cancer Res Proc 2003; 44: 95.
Ye YN, Liu ES, Shin VY, Wu WK, Luo JC, Cho CH . Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther 2004; 308: 66–72.
Ye YN, Wu WKK, Shin VY, Cho CH . A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur J Pharmacol 2005; 519: 52–7.
Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE . Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 1999; 59: 360–6.
Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A . Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectaladenocarcinomas. Gastroenterology 2003; 124: 57–70.
Kennedy TJ, Talamonti M, Ujiki M, Ding XZ, Ternent CA, Bell RH Jr, et al. Lipoxygenase expression in colon polyps and inhibition of colon cancer growth by lipoxygenase blockade. J Am Coll Surg 2004; 199: 78.
Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, et al. Expression of 5-Lipoxygenase in human colorectal cancer. Gastroenterology 2006; 12: 6355–60.
Öhd JF, Wikström K, Sjölander A . Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 2000; 119: 1007–18.
Dahlen SE, Haeggstrom JZ, Samuelsson B, Rabe KF, Leff AR . Leukotrienes as targets for treatment of asthma and other diseases. Current basic and clinical research. Am J Respir Crit Care Med 2000; 161: S1.
Chen X, Wang S, Wu N, Rao SM, Buchler MW, Friess H . Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004; 10: 6703–09.
Hennig R, Grippo P, Ding XZ, Rao SM, Buchler MW, Friess H, et al. 5-lipoxygenase, a marker for early pancreatic pancreatic intraepithelial neoplastic lesions. Cancer Res 2005; 65: 6011–6.
Gronert K, Martinsson-Niskanen T, Ravasi S, Chiang N, Se CN . selectivity of recombinant human leukotrienes D4, leukotrienes B4 and lipoxins A4 receptors with aspirin-triggered 15 epi-LXA4 and regulation of vascular and inflammatory responses. Am J Pathol 2001; 158: 3–9.
Emerson MR, LeVine SM . Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 2004; 17: 140–5.
Groser T, Fries S, FitzGerald GA . Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
Goossens L, Pommery N, Henichart JP . COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr Topics Med Chem 2007; 7: 283–96.
Leval X, Julemont F, Delarge J, Pirotte B, Dogne JM . New trends in dual 5-LOX/COX inhibition. Curr Med Chem 2002; 9: 941–62.
Horizoe T, Nagakura N, Chiba K, Shirota H, Shinoda M, Numata H, et al. Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice. Inflamm Res 1999; 48: 432–6.
Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP . Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003; 62: 501–9.
Kirchner T, Aparicio B, Argentieri DC, Lau CY, Ritchie DM . Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 417–23.
Waldman SA, Vitow C, Osborne B, Gillen L, Argentieri DC, Wong FA, et al. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. J Clin Pharmacol 1996; 36: 462–8.
Depre M, Van Hecken A, Verbesselt R, Verpooten GA, Arnout J, Brunner F, et al. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. Int J Clin Pharmacol Res 1996; 16: 1–8.
Klesser B, Bias P, Buchner A, Elsaesser R . Licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, has little or no effect on the gastric mucosa after 4 weeks of treatment. Ann Rheum Dis 2002; 61: 130.
Alvaro-Gracia JM . Licofelone—clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology 2004; 43: i21–5.
Levy DE, Lee CK . What does Stat3 do? J Clin Invest 2002; 109: 1143–8.
Bowman T, Garcia R, Turkson J, Jove R . STATs in oncogenesis. Oncogene 2000; 19: 2474–88.
Ma XT, Wang S, Ye YJ, Du RY, Cui ZR, Somsouk M . Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 2004; 10: 1569–73.
Christine R, Sylvie R, Erik B, Geneviève P, Amélie R, Gérard R, et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) - and vascular endothelial growth factor-mediated cellular invasion and tumor growthh. Cancer Res 2005; 65: 195–202.
Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005; 7: 545–55.
Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005; 167: 969–80.
Bromberg J . Stat proteins and oncogenesis. J Clin Invest 2002; 109: 1139–42.
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98: 295–303.
Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351–62.
Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, et al. Cooperative regulation of Mcl-1 by Janus kinase/Stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol 2001; 166: 7486–95.
Shen Y, Devgan G, Darnell JE Jr, Bromberg JF . Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 2001; 98: 1543–8.
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive STAT3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000–8.
Wei WD, Le X, Zheng L, Wang L, Frey JA, Gao AC . STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastatis. Oncogene 2003; 22: 319–29.
Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr . Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553–8.
Turkson J, Bowman T, Garcia R, Caldenhoven E, Rolf P, De Groot RP, et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18: 2545–52.
Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C . Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296: 1000–4.
Brummelkamp TR, Bernards R, Agami R . Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243–7.
Xia H, Mao Q, Eliason SL, Harper SQ, Martins HI, Orr HT, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816–20.
Lv W, Zhang C, Hao J . RNAi technology: A revolutionary tool for the colorectal cancer therapeutics. World J Gastroenterol 2006; 12: 4636–9.
Huang ZG, Ran ZH, Lu W, Xiao SD . Analysis of gene expression profile in colon cancer using the Cancer Genome Anatomy Project and RNA interference. Chin J Dig Dis 2006; 7: 97–102.
George SC, Bharati B . Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol 2006; 28: 543–9.
Jiang M, Milner J . Bcl-2 constitutively suppresses p53-depen-dent apoptosis in colorectal cancer cells. Genes Dev 2003; 17: 832–7.
Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the beta-catenin pathway. Proc Natl Acad Sci USA 2005; 102: 6027–32.
Hammond SM, Caudy AA, Hannon GJ . Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001; 2: 110–9.
Bartel DP, Chen CZ . Micromanagers of gene expression: the potentially widespread influence of metazoan micro-RNAs. Nat Rev Genet 2004; 5: 396–400.
Miska EA . How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15: 563–8.
Lim LP, Lau NC, Garrett-engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769–73.
Lewis BP, Burge CB, Bartel DP . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB . Prediction of mammalian microRNA targets. Cell 2003; 115: 787–98.
John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS . Human MicroRNA targets. PLoS Biol 2004; 2: e363.
Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, et al. A combined computational-experimental approach predicts human microRNA targets. Genes Dev 2004; 18: 1165–78.
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495–500.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065–70.
Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628–32.
Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LAJ, Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687–92.
Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29.
Calin GA, Croce CM . MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 2006; 66: 7390–4.
Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–66.
Esquela-Kerscher A, Slack FJ . Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–69.
Hammond SM . MicroRNAs as oncogenes. Curr Opin Genet Dev 2006; 16: 4–9.
Chang T-C, Wentzel EA, Kent AO, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745–52.
Michael MZ, O'Connor SM, Van Holst Pellekaan NG, Young GP, James RJ . Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882–91.
Akao Y, Nakagawa Y, Naoe T . MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007; 26: 311–20.
Qiao D, Zeeman AM, Deng W, Looijenga LH, Lin H . Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas. Oncogene 2002; 21: 3988–99.
Liu X, Sun Y, Guo J, Ma H, Li J, Dong B, et al. Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells. Int J Cancer 2006; 118: 1922–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Janakiram, N., Rao, C. Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin 29, 1–20 (2008). https://doi.org/10.1111/j.1745-7254.2008.00742.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00742.x
Keywords
This article is cited by
-
Estimation of Gas Hydrate Saturation Regarding the Hydrate Morphology in Hydrate-Bearing Sands in the Qiongdongnan Basin, South China Sea
Pure and Applied Geophysics (2023)
-
Hydrocarbon generation and expulsion process in the deepwater area of the Qiongdongnan Basin of China: insights from artificial thermal maturation experiments
Journal of Petroleum Exploration and Production Technology (2023)
-
The variation of free gas distribution within the seeping seafloor hydrate stability zone and its link to hydrate formations in the Qiongdongnan Basin
Acta Geophysica (2022)
-
Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer: a study protocol for a double blind randomized controlled trial
Trials (2019)
-
The influence of irregular seafloor topography on the seismic wave field and migration imaging
Acta Oceanologica Sinica (2019)